A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration

Who May Qualify: - Between 50 and 90 years of age - Participants with diagnosis of macular neovascularization secondary to age-related macular degeneration (nAMD) - Study eye with best corrected visual acuity (BCVA) ETDRS Snellen equivalent for dose escalation (Part I) between 20/32 and 20/400 and for expansion (Part II) between 20/25 and 20/200 - Current or previous use of anti-vascular endothelial growth factor (VEGF) treatment in the study eye - Demonstrated a response to anti-VEGF treatment Who Should NOT Join This Trial: - Any condition in the study eye that may prevent visual acuity improvement or interfere with ocular safety or efficacy assessments - History of active ocular infection in the study eye in 6 months prior to screening - Active uncontrolled glaucoma in the study eye - History of uveitis in either eye - Current use of ocular corticosteroids in the study eye - Previous gene therapy - Any significant poorly controlled illness that would preclude study compliance and follow up The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial. Always talk to your doctor about whether this trial is right for you.